Sernova is Awarded Patents in Multiple Countries for Cell Pouch(TM) and Therapeutic Cell Transplanta

Sernova is Awarded Patents in Multiple Countries for Cell Pouch(TM) and Therapeutic Cell Transplantation Technologies

ID: 371150

(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 02/12/15 -- Sernova Corp. (TSX VENTURE: SVA), today announced that the Patent Offices in China, Israel, Singapore and New Zealand have issued Notices of Allowance and issued patents to Sernova for its patent application entitled "Methods and Devices for Cellular Transplantation."

These patents help protect Sernova's entire Cell Pouch™ system, including the Cell Pouch™ itself, as well as the Cell Pouch™ combined with therapeutic cells and surgical tools for cell transplantation. These issued patents, in addition to patent rights already granted or actively being pursued in other countries, will provide Sernova with patent protection through 2030.

"Patent applications on Sernova's technologies are being pursued in multiple countries around the world and we are confident that additional patents will be granted on an international basis," stated Dr. Philip Toleikis, Sernova's President and CEO.

"Potential strategic partners, including major pharmaceutical companies place significant value in issued patents," stated Dr. Philip Toleikis, Sernova's President and CEO. He continued, "Since 2009, we have been relentless at carrying out our strategy to secure exclusive patent rights on our core technologies, to develop an international footprint for our products."

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch™, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova's proprietary local immune protection technology.





Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
or


Ray Matthews & Associates
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
(604) 818-7778

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Threshold Pharmaceuticals Announces Pricing of $30 Million Offering of Common Stock and Warrants ProMetic Receives $11.4 Million Purchase Order from Multinational Client
Bereitgestellt von Benutzer: Marketwired
Datum: 12.02.2015 - 11:13 Uhr
Sprache: Deutsch
News-ID 371150
Anzahl Zeichen: 0

contact information:
Town:

LONDON, ONTARIO



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 347 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Sernova is Awarded Patents in Multiple Countries for Cell Pouch(TM) and Therapeutic Cell Transplantation Technologies"
steht unter der journalistisch-redaktionellen Verantwortung von

Sernova Corp. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Sernova Receives Approval to Extend Term of Warrants ...

LONDON, ONTARIO -- (Marketwired) -- 05/05/17 -- Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage regenerative medicine company, is pleased to announce that it has received TSX Venture Exchange acceptance, to extend t ...

Sernova Completes Private Placement of $4,200,000 ...

LONDON, ONTARIO -- (Marketwired) -- 06/30/16 -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH) is pleased to announce that it has completed a non-brokered private placement of $4.2 mi ...

Alle Meldungen von Sernova Corp.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z